Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Locally Advanced or Metastatic Breast Cancer Clinical Trial

Official title:

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03781063
• Other study ID #: SMX 18001
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 20, 2019
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Sermonix Pharmaceuticals Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor.

The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The secondary objectives are to evaluate:

1. Clinical benefit rate (CBR) and Objective Response Rate (ORR)

2. Duration of response

3. Time to response

4. Overall Survival (OS)

5. Pharmacokinetics of lasofoxifene

6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires

7. Safety of lasofoxifene

8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).

Description:

Lasofoxifene is a potent SERM that has demonstrated in non-clinical models to prevent and treat breast cancer. In a large clinical osteoporosis trial, lasofoxifene reduced the incidence of ER+ breast cancer, which most likely represents a beneficial effect on clinically undetectable breast cancer. The clinical and non-clinical results are not unexpected based on the results seen with tamoxifen and fulvestrant as the mechanisms of action are similar. Moreover, the safety profile of lasofoxifene is well established in postmenopausal women and therefore a clinical trial investigating lasofoxifene for the treatment of breast cancer is scientifically justifiable.

Subjects with ESR1 mutations have endocrine resistance and shorter time to progression when treated with currently approved endocrine therapy. There is an unmet medical need for endocrine agents that can provide greater efficacy in this population. Non-clinical in vitro and in vivo studies with lasofoxifene have demonstrated efficacy. If this benefit translates to subjects with ESR1 mutated breast cancer cells, an important treatment option beyond fulvestrant will be available. The population being recruited in this trial are subjects with advanced breast cancer who have been treated with an AI in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor and who have an ESR1 mutation. The efficacy of endocrine agents in this population has never been prospectively studied. For this reason, this study will evaluate lasofoxifene in a randomized Phase 2 trial against a comparator to better evaluate the magnitude of the effect as well as to provide data to estimate the Phase 3 sample size.

In both non-clinical and clinical studies, fulvestrant has shown activity in ESR1 mutated breast cancer cells and will be used as the comparator in this Phase 2 study to better determine the relative clinical efficacy of lasofoxifene. The FDA approved fulvestrant dose will be used.

A major limiting factor in the administration of fulvestrant is its poor solubility requiring IM injection. The volume of administration limits the dose that can be administered. Initial clinical trials administered 250 mg of fulvestrant in 5 cc of castor oil as a single injection once monthly. Because the IM injections were well tolerated, loading and higher doses were investigated. This was found to have acceptable tolerability and resulted in greater efficacy. Limited by the volume of administration higher doses of fulvestrant cannot be investigated further.

Once the subject has consented to participate in the study, screening tests will be performed within 30 days of enrollment.

All subjects meeting the eligibility criteria will be first stratified into those with visceral metastasis and those without visceral metastasis. Each of these stratified groups will then be further stratified into those with the Y537S ESR1 mutation and those without this particular mutation. Each of the stratified groups will then be randomized 1:1 to receive either 5 mg/d of oral lasofoxifene or fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29, then every 4 weeks thereafter. Treatment will continue until radiographic or clinical evidence of disease progression. Enrolled subjects will be seen every 2 weeks for the first month of treatment and then monthly until progression. Efficacy assessments will be done every 8 weeks.

For subjects randomized to lasofoxifene, blood samples will be drawn to assess the population PK. Serum samples will be collected at each visit starting at Visit 0 (Day 1) through Final/ET visit to measure serum lasofoxifene concentration at time points outlined below. Serum samples for PK analysis will be collected before the time that the next lasofoxifene dose is ingested. The actual time and date of dosing on the previous day as well as dosing on the visit day, and the PK blood sampling time/date must be recorded for all subjects. Pharmacokinetic samples are to be collected before clinical lab blood sampling.

A maximum of 100 subjects will be randomized and it is expected that all subjects enrolled in the study will be treated until documented disease progression. It is estimated that full recruitment into the study will occur within 12 to 18 months with another 12 months of follow up before the primary outcome measure is analyzed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pre- or postmenopausal.

Postmenopausal women are defined as:

1. =60 years of age with no vaginal bleeding over the prior year, or

2. <60 years with "premature menopause" or "premature ovarian failure" manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards, or

3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study and subjects counseled to use appropriate contraception to prevent pregnancy.

2. If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+ and HER2- disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-.

3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting).

4. Locally advanced or metastatic breast cancer with either measurable (according to RECIST 1.1) or non-measurable lesions.

5. At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. Note: a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization.

6. Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.

7. ECOG performance score of 0 or 1.

8. Adequate organ function as shown by:

1. absolute neutrophil count (ANC) >/=1,500 cells/mm3

2. platelet count =100,000 cells/mm3

3. hemoglobin >/=9.0 g/dl

4. ALT and AST levels =2.5 upper limit of normal (ULN) or =5 in the presence of visceral metastasis

5. total serum bilirubin =1.5 X ULN (= 3 X ULN for subjects known to have Gilbert Syndrome)

6. alkaline phosphatase level = 2.5 X ULN

7. creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault formula

8. International normalized ratio (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) <2.0 X ULN.

9. Able to swallow tablets.

10. Able to understand and voluntarily sign a written informed consent before any screening procedures.

Exclusion Criteria:

1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.

2. Presence of brain metastasis.

3. Lymphangitic carcinomatosis involving the lung.

4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.

5. Radiotherapy within 30 days prior to randomization except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization.

6. History of long QTC syndrome or a QTC of >480 ms.

7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted.

8. Any significant co-morbidity that would impact the study or the subject's safety.

9. History of a positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.

10. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.

11. History of vaginal bleeding over the last year unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy).

12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg at Screening.

13. History of non-compliance to medical regimens.

14. Unwilling or unable to comply with the protocol.

15. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.

Related Conditions & MeSH terms

• Breast Neoplasms
• Locally Advanced or Metastatic Breast Cancer

Intervention

Drug:
• Lasofoxifene
Estrogen receptor antagonist antineoplastic agent
• Fulvestrant
Estrogen receptor antagonist antineoplastic agent

Locations

Country	Name	City	State
Canada	CIUSSS de Saguenay-Lac-Saint Jean	Chicoutimi	Quebec
Canada	Jewish General Hospital	Montréal	Quebec
Canada	McGill University Health Centre	Montréal	Quebec
Canada	The Ottawa Hospital	Ottawa	Ontario
Canada	Sunnybrook Health Sciences Center	Toronto	Ontario
Israel	Soroka University Medical Center	Be'er Sheva
Israel	Hadassah Ein Kerem Medical Center	Jerusalem
Israel	Rabin Medical Center	Petah tikva
Israel	Sheba Medical Center	Ramat Gan
United States	Emory University	Atlanta	Georgia
United States	New Jersey Cancer Care and Blood Disorders (JIT)	Belleville	New Jersey
United States	Roswell Park Comprehensive Cancer Center	Buffalo	New York
United States	Tennessee Oncology Chattanooga	Chattanooga	Tennessee
United States	Robert H. Lurie Comprehensive Cancer Center of Northwestern University	Chicago	Illinois
United States	University of Chicago	Chicago	Illinois
United States	TriHealth Cancer Institute	Cincinnati	Ohio
United States	Ohio Health (JIT)	Columbus	Ohio
United States	The Ohio State University - Comprehensive Cancer Center	Columbus	Ohio
United States	Mary Crowley Cancer Research (JIT)	Dallas	Texas
United States	City of Hope Comprehensive Cancer	Duarte	California
United States	Duke University Medical Center	Durham	North Carolina
United States	Summit Medical Group (JIT)	Florham Park	New Jersey
United States	Compassionate Care Research Group	Fountain Valley	California
United States	FMH James M Stockman Cancer Institute (JIT)	Frederick	Maryland
United States	West Cancer Center	Germantown	Tennessee
United States	Hattiesburg Clinic Hematology/Oncology	Hattiesburg	Mississippi
United States	Hawaii Cancer Care (JIT)	Honolulu	Hawaii
United States	Oncology Consultants (JIT)	Houston	Texas
United States	Mayo Clinic Florida	Jacksonville	Florida
United States	HCA Midwest Health	Kansas City	Missouri
United States	Saint Luke's Cancer Institute	Kansas City	Missouri
United States	Comprehensive Cancer Centers of Nevada (JIT)	Las Vegas	Nevada
United States	Rocky Mountain Cancer Centers	Longmont	Colorado
United States	University of Louisville / James Graham Brown Cancer Center	Louisville	Kentucky
United States	Miami Cancer Institute	Miami	Florida
United States	Tennessee Oncology/SCRI	Nashville	Tennessee
United States	Peninsula Cancer Institute	Newport News	Virginia
United States	Ocala Oncology Center (JIT)	Ocala	Florida
United States	Illinois Cancer Care (JIT)	Peoria	Illinois
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Utah Cancer Specialists (JIT)	Salt Lake City	Utah
United States	UCSF Cancer Center	San Francisco	California
United States	Sanford Cancer Center (JIT)	Sioux Falls	South Dakota
United States	Beacon Health (JIT)	South Bend	Indiana
United States	Florida Cancer Specialists	Tallahassee	Florida
United States	Carle Cancer Center	Urbana	Illinois
United States	The Bond Clinic Cancer & Research Center.	Winter Haven	Florida
United States	Yuma Regional Medical Center (JIT)	Yuma	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Sermonix Pharmaceuticals Inc.	Linical Accelovance Group

Countries where clinical trial is conducted

United States,  Canada,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	PFS is defined as the interval from the date of randomization to the earlier date of first documented radiographic progression or death due to any cause	through study completion, an average of 1 year
Secondary	Clinical Benefit Rate (CBR)	CBR is defined as the percentage of all subjects with a complete or partial response; or stable disease for >/=24 weeks.	through study completion, an average of 1 year
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) as assessed by the RECIST 1.1 criteria.	through study completion, an average of 1 year
Secondary	Overall Survival (OS)	OS is defined as time from randomization to death due to any cause.	through study completion, an average of 1 year
Secondary	Incidence of Adverse Events (AEs) and Serious AEs	The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assess at each visit	through study completion, an average of 1 year